<DOC>
	<DOCNO>NCT00333216</DOCNO>
	<brief_summary>The purpose study demonstrate Anecortave Acetate Depot Suspension ( 15 mg 30 mg ) safe effective arrest progression non-exudative ( dry ) age-related macular degeneration patient risk progress exudative ( wet ) age-related macular degeneration .</brief_summary>
	<brief_title>Anecortave Acetate Risk-Reduction Trial ( AART )</brief_title>
	<detailed_description />
	<mesh_term>Anecortave</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Dry AMD study eye , Wet AMD nonstudy eye ; Other protocoldefined inclusion criterion may apply . Under 50 ; Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>